期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

拓扑替康联合顺铂与足叶乙甙联合顺铂一线治疗小细胞肺癌的临床比较研究 被引量：1

暂未订购
导出
摘要 探讨拓扑替康联合顺铂(PT组)与足叶乙甙联合顺铂(EP组)一线治疗小细胞肺癌的近期疗效、生存期和毒副作用。两组疗效无差异。PT组降低脑转移发生率,延长生存期。主要的剂量限制性毒性是骨髓抑制。
作者 滕月娥 刘云鹏 郑美珍 张敬东 金波 赵明芳 孟晓浩
机构地区 中国医科大学附属第一医院肿瘤内科 辽宁省肿瘤医院内科 阜新市第一医院内科
出处 《中国医科大学学报》 CAS CSCD 北大核心 2005年第3期269-270,共2页 Journal of China Medical University
关键词 小细胞肺癌 拓扑替康 顺铂
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献3

  • 1Andrea A, Christan M, Channa D, et al. European organization for research and treatment of caner( EORTC)08957 phase Ⅱ study of topoteacan in combination with cisplatin as second-line treatment of refreactory and sensitive small cell lung cancer [ J ] . Clin Cancer Res,2003,9( 1 ) : 143 - 150.
  • 2Schiller JH,Kim K, ,Hutson P,et al. Phase Ⅱ　 study of topoteacan in patients with extensive stage small cell carcinoma of the lung an eastern cooperative oncology group trial [ J ]. J Clin Oncol, 1996,14(8) : 2345 - 2352.
  • 3张力,宁晓红,毕洪霞,李龙芸.拓扑替康在小细胞肺癌中的应用[J].中国新药杂志,2001,10(10):743-746. 被引量：4

二级参考文献9

  • 1Dennis MJ, Beijnen JH. An Overview of the clinical pharmacology of topotecan[J]. Semin Oncol, 1997, 24(Suppl 5) :S12 - S18.
  • 2Rowinsky EK, Grochow LB, Bendricks CB, et al. Phase I and pharmacologic study of topotacan: a novel topoisomerase I inhibitor [J] .J Clin Oncol, 1992,10(4) :647 - 656.
  • 3Heron JF.Topotecan:an Oncologist's View[J]. The Oncologist,1998, 3(6) :390 - 402.
  • 4Arbuck SG-, Takimoto CH. An overview of topoisomeraseI-targeting agents[J]. Semin Oncol, 1998,135(Suppl 4) :53 - S12.
  • 5McCabe FL, Johnson RK. Comparative activity of oral and parenteral topotecan in murine tumor models: Efficacy of oral topotecan[J]. Cancer Invest, 1994,12(3) :308 - 313.
  • 6Schiller JH, Kim K, Hutson P. Phase Ⅱ study of topotecan in patients with extensive-stage small-cell carcinoma of the lung[J]. J Clin Oncol, 1996, 14(8) :2345 - 2352.
  • 7Jett JR, Day R, Levitt M. Topotecan and paclitaxel in extensive stage small celllung cancer(ED-SCLC)patients without prior therapy[J]. Lung Cancer, 1997, 18(Suppl 1 ):38a
  • 8Pawel J, Schiller JH, Shepherd FA. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer[J] .J Clin Oncol, 1999, 17(2) :658 -667.
  • 9李志勇,郭勇.抗癌药——喜树碱衍生物[J].中国新药杂志,2000,9(9):598-601. 被引量：7

共引文献3

同被引文献51

  • 1刘文,刘勇,谷仲平,阎明亮,张海亮,殷国庆,邱春丽,蒋冬梅,武世民.拓扑替康联合顺铂在小细胞肺癌术前新辅助化疗效果和耐受性[J].中国误诊学杂志,2004,4(11):1790-1792. 被引量：4
  • 2徐建华,周均田,周文伟,姚定泉,易青,周辉.拓扑替康联合顺铂治疗小细胞肺癌的临床研究[J].肿瘤研究与临床,2005,17(1):35-36. 被引量：4
  • 3American Cancer Society: Cancer Facts and Figures 2006. Atlanta,Ga; American Cancer Society, 2006. [2006-08-07]. http://www.cancer.org,Last accessed August 7, 2006.
  • 4中国抗癌协会临床肿瘤学协作专业委员会．2006年．http：／／www．csco．net．cn．(常规每年更新)．
  • 5Okuno SH, Jett JR. Small cell lung cancer: current therapy and promising new regimens. The Oncologist, 2002, 7: 234-238.
  • 6Schiller JH. Current standards of care in small-cell and non-smallcell lung cancer. Oncology, 2001, 61(Suppl 1): 3-13.
  • 7von Pawel J. The role of topotecan in treating small cell lung cancer:second-line treatment. Lung Cancer, 2003, 41 (Suppl 4): $3-$8.
  • 8Topotecan. An Oncologist' View.Centre Francois Baclesse, Centre Regional de Lutte Contre le Cancer, Caen, France. The Oncologist,1998, 3: 390-402.
  • 9Depierre A, von Pawel J, Hans K, et al. Evaluation of topotecan(Hycam-tin(TM)) in relapsed small cell lung cancer (SCLC). A multicentre phase II study. Lung Cancer, 1997, 18(Suppl 1): 35.
  • 10Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Stud-ies Group and New Drug Development Office, andthe Lung Cancer Cooperative Group. d Clin Oncol, 1997, 15: 2090-2096.

引证文献1

二级引证文献4

中国医科大学学报
2005年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部